FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bensen Daniel (Last) (First) (Middle) C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET					3. 02	2. Issuer Name and Ticker or Trading Symbol Tyra Biosciences, Inc. [TYRA] 3. Date of Earliest Transaction (Month/Day/Year) 02/02/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Other (specify below) Chief Operating Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) CARLSE	eet) RLSBAD CA 92008														Form filed by More than One Reporting Person					
(City)	(S	,	(Zip)	Non-Der	X	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. ative Securities Acquired, Disposed of, or Beneficially Owned													d to	
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)				Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A) or			5. Amount of		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)	Price	1	Reported Transact (Instr. 3 a	ction(s)			(IIISTF. 4)		
Common Stock 02/02/20				2024	24			M		25,393	A	\$0.61	1 55		3,374		D			
Common Stock 02/02/				02/02/2	2024	024					73,093	D	\$16.3060	5(2)	⁵⁽²⁾ 480,2		D			
Common Stock 02/02/2				2024	024					2,300	D	\$17.043	.043 ⁽³⁾ 47		7,981		D			
Common Stock 02/06/2			2024	24			S ⁽¹⁾		15,413	D	\$18.0904(4)		462,568			D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any		4. Transa	4. Transaction Code (Instr.		5. Number			cisable and	7. Title a of Secur Underly	ind Amount ities ing ve Security	Deri Sec (Ins	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Number of Shares							
Stock Option (Right to Buy)	\$0.61	02/02/2024			М			25,393	(:	5)	01/26/2030	Common Stock	25,393		\$0	108,11	0	D		

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
- 2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$16.00 to \$16.91. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- 3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$17.00 to \$17.17. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- 4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$18.00 to \$18.44. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- 5. 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.

/s/ Ali D. Fawaz, Attorney-in-02/06/2024 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.